文献速递腹部技术与安全US

超声标志物无创评估MASLD肝脂肪变性的诊断性能

US Markers in the Noninvasive Assessment of Hepatic Steatosis in Metabolic Dysfunction-associated Steatotic Liver Disease.
PubMed 文献 · Radiology · 2026-01-01

本研究为iLEAD前瞻性研究的二次分析,纳入102例经活检证实MASLD的参与者,评估超声衰减系数(AC)、归一化局部方差(NLV)、肝肾比值及其组合对肝脂肪变性分级的诊断性能。AC在各分级中诊断性能最高(≥S1的AUC为0.93),单独AC优于NLV和肝肾比值;组合模型虽未显著提高AUC,但可改善风险重分类。

要点

  • AC是评估MASLD肝脂肪变性的首选超声标志物,≥S1的AUC达0.93。
  • AC联合NLV和肝肾比值虽未显著提高AUC,但可改善脂肪变分级的风险重分类。
  • NLV和肝肾比值单独诊断性能低于AC,但可作为组合模型的补充。

局限性

  • 本研究为二次分析,样本量有限(102例),可能影响结论的普适性。
  • 研究未报告多中心外部验证结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Attenuation coefficient (AC) is an established US marker for assessing patients with liver steatosis. However, improvements in diagnostic performance are warranted. Purpose To evaluate the diagnostic performance of AC, normalized local variance (NLV), hepatorenal ratio, and their combinations for liver histopathologic steatosis in participants with metabolic dysfunction-associated steatotic liver disease (MASLD). Materials and Methods This secondary analysis of the prospective Innovative Liver Elasticity, Attenuation, and Dispersion Ultrasound Study (iLEAD) (June 2019 to March 2023) included participants with biopsy-proven MASLD who underwent multiparametric liver US; AC, NLV, and hepatorenal ratio were measured. The diagnostic performance of each imaging marker and their combinations for determining steatosis grade were assessed using the area under the receiver operating characteristic curve (AUC) with the DeLong test, and reclassification improvement was also assessed using the category-free net reclassification improvement (NRI). Results A total of 102 participants (mean age, 52 years ± 16.1 [SD]; 51 male) were evaluated. AC showed the highest diagnostic performance for determining steatosis grade across all grades (AUC for grade ≥S1, 0.93 [95% CI: 0.87, 0.99]), compared with NLV (0.88 [95% CI: 0.77, 0.99]; P = .47) and hepatorenal ratio (0.85 [95% CI: 0.71, 0.98]; P = .30). Four models were constructed for identifying steatosis grades: model 1, AC only; model 2, AC plus NLV; model 3, AC plus hepatorenal ratio; model 4, AC plus NLV plus hepatorenal ratio. Models 2-4 showed no evidence of a difference in performance from model 1 for identifying grade S1 or higher (AUC, 0.93-0.98; P = .16, .15, and .07, respectively), but an improvement in risk reclassification was observed for model 4 (NRI, 1.18 [95% CI: 0.54, 1.77]; P < .001) compared with model 1 (reference). Performance was similar across models in identifying steatosis grade S2 or greater (AUC, 0.89-0.90; all P ≥ .47) and for grade S3 (AUC, 0.89-0.90; all P ≥ .72), but an improvement in risk reclassification was observed for model 3 compared with model 1 (≥S2 steatosis: NRI, 0.58 [95% CI: 0.20, 0.94] [P = .002]; S3 steatosis: NRI, 0.71 [95% CI: 0.26, 1.14] [P = .002]). Conclusion Liver US-derived AC performed better than NLV and hepatorenal ratio in determining steatosis grade in participants with MASLD; when these markers were combined, reclassification of steatosis grade improved. Clinical trial registration no. NCT04012242

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Sugimoto K, Moriyasu F, Dioguardi Burgio M, et al. US Markers in the Noninvasive Assessment of Hepatic Steatosis in Metabolic Dysfunction-associated Steatotic Liver Disease. Radiology. 2026. PMID: 42937537. doi:10.1148/radiol.260360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。